Major study reassures parents about acetaminophen and ibuprofen use in babies
New research finds common pain relievers do not increase risk of eczema or bronchiolitis in infants
1Concerns about painkiller use in infants
Previous studies had suggested that acetaminophen (Tylenol) use during infancy might be linked to eczema, asthma, or other health conditions. These concerns created uncertainty among parents and healthcare professionals about the safety of common pain relievers. The New Zealand research team launched a comprehensive study to directly address these concerns.
2Study scope and methodology
The PIPPA Tamariki study followed approximately 4,000 babies from birth in New Zealand. Infants were randomly assigned to two groups: one received acetaminophen for fever or pain, while the other received ibuprofen. Researchers regularly collected information from parents about whether their children had experienced eczema, asthma symptoms, or bronchiolitis. Prescription information and hospital records were also reviewed.
3Striking findings
Findings published in The Lancet Child & Adolescent Health revealed eczema in 16% of babies in the acetaminophen group compared to 15% in the ibuprofen group. Bronchiolitis affected about 5% in each group. These differences were not statistically significant. Serious side effects were rare and none were attributed to either medication.
4Significance of the research
This study is the first randomized controlled trial - considered the gold standard in medical research - to directly examine this question. The findings give parents and healthcare professionals confidence to continue using these important medications. The results provide strong reassurance about the safety of these commonly used pain relievers.
5Long-term follow-up plans
The research team plans to follow participants until age six. Results from three-year-old children will be published soon, followed by findings at age six. This long-term follow-up will help determine whether painkiller use is associated with health conditions that can be more reliably diagnosed as children grow older.
6Expectations regarding asthma development
Lead researcher Professor Stuart Dalziel notes, "We know that two-thirds of children who are wheezy at age three don't develop asthma by age six." Therefore, waiting until school age is necessary to definitively test whether acetaminophen use in the first year causes asthma. This long-term data will provide important clinical outcomes.
7Examination of developmental disorders
The study will also examine developmental conditions such as autism and attention deficit hyperactivity disorder (ADHD), which are typically diagnosed more accurately as children grow. Senior author Dr. Eunicia Tan states the study will provide important evidence regarding links between acetaminophen use and asthma, eczema, hay fever, and developmental disorders.
8Practical implications for parents
Findings from this comprehensive study enable parents to treat fever or pain in their infants with greater confidence. Conducted by the University of Auckland and the Medical Research Institute of New Zealand, Wellington, and funded by the Health Research Council of New Zealand and Cure Kids, the results will play a significant role in informing global pediatric practices.